Institutional members access full text with Ovid®

Share this article on:

ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE

Diez-Domingo, Javier MD, PhD*†; Planelles-Cantarino, M. Victoria MD†; Baldo-Torrenti, Jose M. MD†; Ubeda-Sansano, Isabel MD, PhD†; Jubert-Rosich, Angels MD†; Puig-Barbera, Joan MD, PhD*; Gutierrez-Gimeno, M. Victoria PhD*

Pediatric Infectious Disease Journal: August 2010 - Volume 29 - Issue 8 - pp 768-770
doi: 10.1097/INF.0b013e3181d9e653
Brief Reports

We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197.

Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4–616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5–71.3) when MenC-CRM197 conjugate was used.

From the *Centro Superior de Investigación en Salud Pública (CSISP), Valencia, Spain; and †Vaccine Institute of Valencia (VIVA), Valencia, Spain.

Accepted for publication February 17, 2010.

Supported by Dirección General de Salud Pública, Valencia, Spain. EudraCT 2006-003525-82, and Clinicaltrials.Gov identifier NCT00392808.

Address for correspondence: Javier Diez-Domingo, MD, PhD, Centro Superior de Investigación en Salud Publica (CSISP), Valencia, Avda Catalunya 20, 46021 Valencia, Spain. E-mail: diez_jav@gva.es.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).

© 2010 Lippincott Williams & Wilkins, Inc.